MP-RM-1
Based on 1 Customer Validation
MP-RM-1 is an antibody-based, non-competitive ErbB-3 inhibitor with a Kd value of 32.7 nM. MP-RM-1 inhibits both ligand-dependent and ligand-independent ErbB-3 activation, blocks ErbB-2/ErbB-3 heterodimerization, induces ErbB-3 internalization and degradation, and suppresses the phosphorylation of downstream Akt. MP-RM-1 exerts its antagonistic effect through a non-competitive mechanism. MP-RM-1 inhibits tumor growth in melanoma and prostate cancer xenograft models in nude mice and reduces the proliferative activity of tumor cells.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 96.29%
- 분자량:147.86 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Human IgG1 kappa
Human
|
ErbB3 32.7 nM (Kd) |
MP-RM-1 (0.01-10 μg/mL; 15-120 min) inhibits NRG-1β-dependent phosphorylation of ErbB-3 and Akt in a dose- and time-dependent manner in breast cancer cells MDA-MB-435 and melanoma cells IR-8[1].
MP-RM-1 (10 μg/mL) significantly inhibits the colony-forming ability of IR-8 melanoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MP-RM-1 (20 mg/kg; i.p.; twice weekly) significantly inhibits the growth of DU-145 prostate cancer xenografts in nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 nu/nu (7-weeks old, melanoma xenograft via subcutaneous injection of IR-8 cells)[1]
-
Dosage:20 mg/kg (tumor growth delay); 20 mg/kg (tissue analysis)
-
Administration:i.p.; twice weekly (tumor growth delay); i.p.; single injection (tissue analysis)
-
Result:Caused significant tumor growth delay over 8 weeks.
Reduced ErbB-3 expression and Akt phosphorylation significantly compared to controls.
Decreased Ki-67 staining index to 35.8 vs 57.9 in controls (P = 0.048).
Decreased mitotic index to 6.6 vs 9.5 in controls (P = 0.017).
-
Animal Model:CD-1 nu/nu (7-weeks old, prostate cancer xenograft via subcutaneous injection of DU-145 cells)[1]
-
Dosage:20 mg/kg
-
Administration:i.p.; twice weekly
-
Result:Caused significant tumor growth delay over 4 weeks.
Induced statistically significant differences in tumor volume relative to controls at multiple time points.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized huHER3-Fc can bind MP-RM-1. The EC50 for this effect is 19.07 ng/mL.
Chemical Information
-
Appearance Liquid
-
분자량 147.86 kDa
-
Color Colorless to off-white
-
SMILES
N/A
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MP-RM-1 Related Classifications
HY-P991243 Related Classifications
Powered by Bioz